Gabriella Fiume-Campadelli
Bologna, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Therapeutic vaccination for glioblastoma elicited by retargeted oncolytic herpes virus.
Journal: Journal for immunotherapy of cancer
Published: December 19, 2025
Gnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment.
Journal: Journal for immunotherapy of cancer
Published: July 07, 2025
Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers.
Journal: Frontiers in molecular biosciences
Published: June 05, 2024
Decrease in Heparan Sulphate Binding in Tropism-Retargeted Oncolytic Herpes Simplex Virus (ReHV) Delays Blood Clearance and Improves Systemic Anticancer Efficacy.
Journal: Cancers
Published: January 11, 2024
Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses-Clearance and Biodistribution in Naïve and HSV-Preimmune Mice.
Journal: Cancers
Published: July 18, 2023
Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers.
Journal: Frontiers in molecular biosciences
Published: January 23, 2023
Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV.
Journal: Viruses
Published: July 23, 2021
Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.
Journal: Advances in experimental medicine and biology
Published: February 09, 2021
Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line.
Journal: Cancers
Published: October 30, 2020
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment.
Journal: Molecular therapy oncolytics
Published: February 21, 2020
Last Updated: 09/26/2026